Literature DB >> 12163193

Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase.

Hirofumi Ochi1, Manabu Osoegawa, Xiao-Mu Wu, Motozumi Minohara, Izumi Horiuchi, Hiroyuki Murai, Hirokazu Furuya, Jun-ichi Kira.   

Abstract

In the present study, we flow cytometrically analyzed the intracellular production of interleukin (IL)-5 and IL-13 in peripheral blood CD4(+) and CD8(+) T cells from patients with multiple sclerosis (MS), human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and healthy controls. IL-13-producing T cells were significantly increased in both T cell subsets in MS at relapse, markedly in the conventional form of MS and modestly in the optocospinal form of MS, and returned to normal at remission. However, IL-5-producing T cells did not vary regardless of clinical phase or type. HAM/TSP showed no significant change in the number of IL-5- and IL-13-producing cells. A distinct profile of IL-13 and IL-5 production by disease and by phase of MS suggests an active involvement of these type 2 cytokines in central nervous system (CNS) inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163193     DOI: 10.1016/s0022-510x(02)00189-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

Review 1.  T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Authors:  Itay Raphael; Saisha Nalawade; Todd N Eagar; Thomas G Forsthuber
Journal:  Cytokine       Date:  2014-10-30       Impact factor: 3.861

2.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Authors:  George P Christophi; Jennifer A Christophi; Ross C Gruber; Cornelia Mihai; Luis J Mejico; Paul T Massa; Burk Jubelt
Journal:  J Neurol Sci       Date:  2011-06-11       Impact factor: 3.181

3.  Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosis.

Authors:  Chris Juul Hedegaard; Christian Enevold; Finn Sellebjerg; Klaus Bendtzen; Claus Henrik Nielsen
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

4.  Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Chriso Tsikkou; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

5.  Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis.

Authors:  Zohara Sternberg; Cassandra Hennies; Daniel Sternberg; Ping Wang; Peter Kinkel; David Hojnacki; Bianca Weinstock-Guttmann; Frederick Munschauer
Journal:  J Neuroinflammation       Date:  2010-10-29       Impact factor: 8.322

6.  Akt3-Mediated Protection Against Inflammatory Demyelinating Disease.

Authors:  Juwen C DuBois; Alex K Ray; Ross C Gruber; Yongwei Zhang; Ranee Aflakpui; Fernando Macian-Juan; Bridget Shafit-Zagardo
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

7.  GAS6 signaling tempers Th17 development in patients with multiple sclerosis and helminth infection.

Authors:  Juan M Ortiz Wilczyñski; Cinthia M Olexen; Andrea E Errasti; Mirta Schattner; Carla V Rothlin; Jorge Correale; Eugenio A Carrera Silva
Journal:  PLoS Pathog       Date:  2020-12-21       Impact factor: 6.823

8.  Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Rebecca L Christophi; Ross C Gruber; Akos T Mersich; Scott D Blystone; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2009-04-27       Impact factor: 5.662

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.